LAU-7b has shown potent antiviral effects against SARS-CoV-2 and MERS-CoV coronaviruses, and is also being developed for its anti-inflammatory properties.
COVACTA trial did not meet primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoints.
Studies will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of JS016 in healthy participants who have not been diagnosed with COVID-19.
Clinical study will explore the potential of TJM2, a mAb against Cytokine Release Syndrome, which is an overreaction of the immune system caused by inflammation